The eQUANT System delivers antibiotic susceptibility testing results in 70 minutes, cutting turnaround time by up to 24 hours.
Avails Medical Inc has signed its first US commercial customer for the company’s eQUANT System, marking a milestone for the Menlo Park, California-based developer of rapid antibiotic susceptibility testing (AST) technology.
The customer is an academic medical center that serves as the flagship hospital for a six-hospital system. The eQUANT System will support the hospital system’s efforts to deliver faster results for sepsis patient management.
The eQUANT System delivers standardized inoculum results directly from positive blood cultures in approximately 70 minutes, shortening routine AST turnaround time by up to 24 hours compared to traditional methods. The technology uses a fully electrical platform to enable faster, targeted antimicrobial therapy decisions.
“I am so proud of the Avails team for this accomplishment and installing the first eQUANT Systems at such a prestigious institution,” says Oren Knopfmacher, PhD, co-founder and CEO of Avails Medical, in a release. “It truly is a testament to how novel and impactful the eQUANT System is in speeding up the time to actionable results for the sickest patients.”
System Features and Laboratory Integration
The eQUANT System features a compact design with a user-friendly interface designed to integrate into existing laboratory workflows. The system’s electrical biosensor technology eliminates manual culturing steps typically required for pathogen quantification and susceptibility testing.
The platform addresses antibiotic resistance challenges by providing rapid susceptibility data to guide appropriate therapy selection. By reducing the time between positive blood culture and actionable AST results, the system aims to improve patient outcomes while supporting laboratory efficiency goals.
Commercial Leadership Appointment
Concurrent with the commercial milestone, Avails Medical appointed Jason Kniebel as vice president of sales. Kniebel brings more than 20 years of experience in life sciences and diagnostics sectors, most recently serving as vice president of sales at T2 Biosystems.
“I am honored to join the incredible team at Avails Medical, which is committed to improving patient outcomes and fighting antimicrobial resistance through innovative, affordable, and rapid testing solutions,” says Kniebel in a release. “I look forward to leading the effort to drive sustainable business growth now and into the future.”
The eQUANT System represents Avails Medical’s entry into the commercial AST market, where rapid turnaround times are increasingly important for sepsis management and antimicrobial stewardship programs. The company’s proprietary electronic biosensor technology platform is designed to work directly with human specimens without requiring traditional culture-based preparation steps.
Photo caption: The Avails Medical eQUANT™ system
Photo credit: Avails Medical
